Ching Lick C. L. Tong

Dr. Ching Lick C. L. Tong

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in International Forum of Allergy & Rhinology
Verified
Journal Article
Open access
Edward C KuanEdward C Kuan
Edward C Kuan
EWEric W Wang
Eric W Wang
NANithin D. Adappa
Nithin D. Adappa
DBDaniel M Beswick
Daniel M Beswick
NLNyall R. London
Nyall R. London
JPJames N. Palmer
James N. Palmer
Background: Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field.Methods: In accordance with prior International Consensus Statement on Allergy and Rhinology documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on the level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication.Results: The ICSNT document consists of four major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.Conclusion: As an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.

25 July 2011 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
EGEric M. Genden
Eric M. Genden
TKTamar Kotz
Tamar Kotz
CTChing Lick C. L. Tong
Ching Lick C. L. Tong
CSClaris Smith
Claris Smith
ASAndrew G. Sikora
Andrew G. Sikora
JKJohnny Kao
Johnny Kao

1 December 2007 in Addictive Behaviors
Verified
Journal Article
Closed access
CTChing Lick C. L. Tong
Ching Lick C. L. Tong
DBDana H. Bovbjerg
Dana H. Bovbjerg
JEJoel Erblich
Joel Erblich

10 May 2013 in Targeted Oncology
Verified
Journal Article
Closed access
PDF file
JKJohnny Kao
Johnny Kao
CCChien-Ting Chen
Chien-Ting Chen
CTChing Lick C. L. Tong
Ching Lick C. L. Tong
SPStuart H. Packer
Stuart H. Packer
MSMyron Schwartz
Myron Schwartz
MSMax W. Sung
Max W. Sung

27 June 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CTChing Lick C. L. Tong
Ching Lick C. L. Tong
EKEric C. Ko
Eric C. Ko
MSMax W. Sung
Max W. Sung
JCJamie A. Cesaretti
Jamie A. Cesaretti
RSRichard G. Stock
Richard G. Stock
JKJohnny Kao
Johnny Kao
Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant metastases. Twenty five patients with oligometastases, defined as 1–5 sites of active disease on whole body imaging, were enrolled in a phase II trial from 2/08 to 9/10. The most common tumor types treated were head and neck, liver, lung, kidney and prostate cancers. Patients were treated with the recommended phase II dose of 37.5 mg daily sunitinib (days 1–28) and IGRT 50 Gy (days 8–12 and 15–19). Maintenance sunitinib was used in 33% of patients. Median follow up was 17.5 months (range, 0.7 to 37.4 months). The 18-month local control, distant control, progression-free survival (PFS) and overall survival (OS) were 75%, 52%, 56% and 71%, respectively. At last follow-up, 11 (44%) patients were alive without evidence of disease, 7 (28%) were alive with distant metastases, 3 (12%) were dead from distant metastases, 3 (12%) were dead from comorbid illness, and 1 (4%) was dead from treatment-related toxicities. The incidence of acute grade ≥ 3 toxicities was 28%, most commonly myelosuppression, bleeding and abnormal liver function tests. Concurrent sunitinib and IGRT achieves major clinical responses in a subset of patients with oligometastases. ClinicalTrials.gov NCT00463060

28 March 2012 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
CTChing Lick C. L. Tong
Ching Lick C. L. Tong
JKJohnny Kao
Johnny Kao
ASAndrew G. Sikora
Andrew G. Sikora